HARTFORD, Conn. — Aetna, a CVS Health company, announced Thursday that over 81% of its Medicare Advantage (MA) members are in 2026 Medicare Advantage Prescription Drug (MAPD) plans that are rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). Additionally, over 63% of Aetna Medicare Advantage members are in a 4.5-star plan for 2026.
"This year's Star Ratings reflect Aetna's strong fundamentals and unwavering commitment to delivering exceptional care experiences and better health outcomes for our Medicare Advantage members," says Aetna president Steve Nelson. "I am proud of the way our teams show up every day to support our members, enabling Aetna to serve as their trusted, reliable health care partner."
The company says Aetna continues to be an industry leader in providing high-quality Medicare solutions, consistently ranking among the top tier of large publicly traded companies in CMS Star Ratings.
